Diaceutics (LON:DXRX) Receives Buy Rating from Canaccord Genuity Group
Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX – Free Report) in a research note published on Tuesday morning, MarketBeat reports. The firm currently has a GBX 180 ($2.43) target price on the stock. Separately, Royal Bank Of Canada reduced their price objective on Diaceutics from GBX 195 ($2.63) to GBX […]
More Stories
Oversight Committee Probes Alleged Cover-Up of Massive Minnesota Welfare Fraud
By Janice Hisle Citing whistleblowers’ allegations that Minnesota officials covered up or ignored massive welfare fraud, a powerful congressional committee...
US Border Patrol to Charge $5,000 Apprehension Fee for Illegal Border Crossers
By Aldgra Fredly The U.S. Border Patrol announced on Dec. 5 that it will impose a $5,000 apprehension fee on...
Bobby Lee’s Net Worth And His Journey To Success
One of the oldest comedians from the US, Bobby Lee, has spent around 30 years in the field of comedy,...
UK Sanctions Russia After Inquiry Holds Putin Responsible for 2018 Novichock Poisonings
By Guy Birchall The UK issued new sanctions on Russia on Dec. 4, after a public inquiry into the death...
Indiana House Passes New Congressional Map Favoring Republicans
By Arjun Singh The Indiana House of Representatives on Dec. 5 passed a bill that would revise the state’s maps...
Economists Forecast Stronger US Growth, Lingering Inflation in 2026
By Tom Ozimek The U.S. economy will grow faster next year than previously projected and inflationary pressures will tick down,...